Cluepoints

Co-founder Marc Buyse holds a ScD in biostatistics from the Harvard School of Public Health and previously worked at the Dana Farber Cancer Institute. His background includes founding the International Drug Development Institute (IDDI) in 1991. Patrick Hughes has over 20 years of international experience in life sciences and healthcare IT, having previously held roles at ClinPhone Ltd. and Exco InTouch Ltd. Francois Torche has a background in business administration and spent over two decades in the pharmaceutical industry as a statistical programmer and IT project leader for companies like GSK and UCB.

The company's software platform offers an end-to-end solution, from initial risk assessment to monitoring and tracking issues throughout the drug development process. Key products include the Site Profile and Oversight Tool (SPOT), Intelligent Medical Coding (IMC), Intelligent Query Detection (IQD), and Medical & Safety Review (MSR). These tools are designed to automate data discrepancy detection, improve medical review efficiency, reduce manual coding, and provide adaptive site monitoring. The software helps ensure compliance with regulatory guidance from bodies such as the FDA and EMA.

CluePoints has experienced significant growth, transitioning from a single-product to a multi-product platform company in 2024. The company has raised a total of $6.55M over two funding rounds. It received a Series A investment from Summit Partners in 2020 and was later acquired by EQT in June 2024, with Summit Partners and co-founder Clinimetrics SA retaining minority stakes. As of 2024, the platform had over 9,500 users and had been used to de-risk more than 1,600 studies.